Orally administered vaccine can protect millions from hepatitis B. Oral vaccines are both safer and less expensive than injections. Therefore, researchers are continuously pursuing ways to produce an oral vaccine that is sufficiently effective. Now, University of Copenhagen physicists have delivered virologists a “recipe” for improving vaccine drops using methods from the world of nanophysics.
Millions of people are infected with hepatitis B every year. Hundreds of thousands die. And small children are particularly at risk. Due to high cost and the stable environmental conditions required for vaccine storage, many people in developing countries are not vaccinated against this dangerous virus. As such, researchers have been working to produce a drop or powdered form of oral vaccine. Oral vaccinations are cheaper and more easily administered than injections. However, developing a sufficiently effective oral hepatitis B vaccine has so far eluded researchers.
A joint collaboration from physicists at the Niels Bohr Institute, a team of researchers from University of São Paulo together with the Butantan Institute has introduced a technique to the pharmaceutical world that just might do the trick and lead to an optimal oral Hepatitis B vaccine.
“We have used a technology commonly used in solid state physics to explore how the vaccine behaves within a particular type of encapsulation. This has yielded crucial information that would not otherwise have been achievable. When we scientists venture beyond our comfort zone and deploy each other’s knowledge across disciplines, entirely new possibilities can emerge,” says Heloisa Bordallo, an associate professor at the Niels Bohr Institute, and one of the two main authors of the research article just published in Scientific Reports.
Three dimensional insight
A major challenge of making an oral vaccine is to encapsulate it in a material that can endure the harsh conditions of our digestive system, to protect the vaccine from being destroyed before it reaches its intended destination in the body. The Danish research team’s collaborative partners in Brazil have long known that the silica-material SBA-15 is well-suited to encapsulate a hepatitis B vaccine. However, they did not know exactly how the material protected the vaccine. Nor were they certain about why their vaccine was not always completely effective.
This is where the team of Danish physicists came into the picture. Using a special technique that combines x-ray and neutron imaging, researchers at the Niels Bohr Institute were able to produce 3D images of the inside of the SBA-15 silica. It marked a crucial step in the use of this technique to develop pharmaceuticals. The imagery allows researchers to see how the vaccine behaves inside the silica, right down to the particle scale. Among other things, they were able to see that the vaccine had a tendency to clump within the silica, making it less effective.
“Now we know what makes the vaccine less effective, and how to optimize it. We know exactly how much vaccine should be put in the silica capsule for it to work best in the body and the clinical trials can be better interpreted,” explains Heloisa Bordallo.
No more swelling and inflammation
The vaccine is particularly promising for developing nations, explains the other main author, Martin K. Rasmussen, a former student at the Niels Bohr Institute and current doctoral student at DTU:
“Getting rid of needles being poked into the arms of little children is an advantage in and of itself. It also eliminates any need to sterilize needles and possible side effects such as swelling and infection. And, unlike the vaccine in use today, this type of vaccine needn’t be refrigerated. As such, costs will be reduced and the vaccine’s administration will be eased.”
The researchers hope that the 3D technology will also be used to develop oral vaccines against several other types of disease. The goal of the Danish researchers’ Brazilian collaborative partners is to produce a 6-in-1 oral vaccine against diphtheria, tetanus, whooping cough, polio, Hib and hepatitis B. The vaccine against diphtheria and tetanus is already being developed.
Learn more: Needleless vaccine will protect children from dangerous viruses
The Latest on: Oral vaccines
via Google News
The Latest on: Oral vaccines
- Immunology taught by vaccineson November 28, 2019 at 11:50 am
However, the effects of the antibiotic azithromycin were examined on the immunogenicity of oral polio vaccine in seronegative infants in India, and the antibody response was unaffected (10). Of note, ...
- Tailoring vaccines for older people and the very youngon November 27, 2019 at 6:09 am
Newborns respond well to the bacillus Calmette–Guérin (BCG) vaccine against tuberculosis, the oral polio vaccine and hepatitis B vaccines. The challenge is to work out why those vaccines work, and use ...
- Global Polio Vaccine Market- Future Study, Research Methodology, Rising Demand, Future Opportunities and Outlook, 2027on November 27, 2019 at 4:11 am
The market is segmented by product type into inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV). Among these segments, oral poliovirus vaccine (OPV) segment is anticipated to hold ...
- Peanut Allergy Vaccine Market Insights to See Incredible Growth and Forecast by 2026on November 26, 2019 at 11:09 pm
Some of the other treatment methods for peanut allergy are oral immunotherapy and epinephrine treatment. However, neither of these treatments has gained significant momentum in the peanut allergy ...
- Vaccination-wary groups call for halt of oral polio vaccineon November 26, 2019 at 9:56 pm
Vaccination-wary groups are calling for the World Health Organization to halt the use of an oral polio vaccine following reports of 11 new cases of polio attributed to the vaccine in five countries.
- Prokarium Announces MHRA Acceptance to Run Phase I Trial of Lead Vaccine Against Enteric Feveron November 26, 2019 at 4:07 pm
About Entervax™ Entervax™ is an oral, bivalent vaccine based on the Vaxonella ® platform and is the combination of Prokarium’s proprietary strain ZH9 (Salmonella enterica serovar Typhi ZH9), which has ...
- Report raises concern about rare polio cases caused by oral vaccineon November 25, 2019 at 1:47 pm
LONDON (AP) — Four African countries have reported new cases of polio linked to the oral vaccine, as global health numbers show there are now more children being paralyzed by viruses originating in ...
- More polio cases now caused by vaccine than by virus in wildon November 25, 2019 at 7:26 am
Four African countries have reported new cases of polio linked to the oral vaccine, as global health numbers show there are now more children being paralyzed by viruses originating in vaccines than by ...
- Global Human Vaccine Market 2018-2022 | Evolving Opportunities with GlaxoSmithKline and Merck | Technavioon November 25, 2019 at 7:04 am
Request free sample pages This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191125005370/en/ Read the 121-page report with TOC on “Human ...
- Cancer Vaccine 2019 Global Share, Trend, Market Size, Industry Growth, Opportunities and Forecast to 2025on November 25, 2019 at 3:08 am
are – HPV Vaccine & Hepatitis B Vaccine. The former helps in protecting the body from anal cancer, genital warts, cervical, vaginal and vulvar cancer. Rumors suggest that oral cancer can also be ...
via Bing News